Icotrokinra vs Semaglutide
Overview
Icotrokinra is primarily a immune support peptide, while Semaglutide is used for weight management & metabolic.
This page compares Icotrokinra and Semaglutide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Semaglutide | |
|---|---|---|
| Category | Immune Support | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 0.25-2.4 mg |
| Frequency | — | weekly |
| Reported benefits | — | Significant weight loss, improved blood sugar control, reduced cardiovascular risk, appetite suppression |
| Reported side effects | — | Nausea, vomiting, diarrhea, constipation, potential pancreatitis risk |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Semaglutide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Icotrokinra: FDA-approved. Semaglutide: FDA-approved.
Dosing. Typical dosing for Icotrokinra is not catalogued. Semaglutide is typically dosed at 0.25-2.4 mg (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Semaglutide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Semaglutide?
- Icotrokinra is primarily a immune support peptide, while Semaglutide is used for weight management & metabolic. Icotrokinra is FDA-approved for one or more indications, whereas Semaglutide is FDA-approved for one or more indications.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Semaglutide used for?
- Weight loss, blood sugar control.
- Can you take Icotrokinra and Semaglutide together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Semaglutide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Semaglutide FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Semaglutide is FDA-approved for one or more indications.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Semaglutide — full monograph: mechanism, research, dosing & references